Key Highlights
• EVMN shares fell 1.39% intraday to $13.11 after the company reported Phase 2b trial results for EVO756.
• The trial did not meet its primary endpoint in patients with moderate-to-severe chronic spontaneous urticaria.
• Evommune will continue developing EVO756 in atopic dermatitis and migraine indications.
• The company maintains a cash runway supporting operations through 2028.
Phase 2b Trial Misses Primary Endpoint
Evommune, Inc. (NYSE:EVMN) shares declined after the company announced that its Phase 2b trial of EVO756 in adults with moderate-to-severe chronic spontaneous urticaria did not meet its primary endpoint of mean change in Urticaria Activity Score at 12 weeks, across any of the three active dose regimens tested.
Evommune is a Palo Alto, California-based clinical-stage biotechnology company developing oral therapies targeting key drivers of chronic inflammatory and immune-mediated diseases, with EVO756, a selective MRGPRX2 antagonist, as one of two lead pipeline candidates.
Pipeline Continues in Other Indications
Company leadership said the trial confirmed safe and well-tolerated doses that support continued development of EVO756 in other indications, including atopic dermatitis, where top-line Phase 2b data is expected in the third quarter of 2026, and migraine prophylaxis, where patient dosing is expected to begin imminently. The company also highlighted positive Phase 2a proof-of-concept data for EVO301, its IL-18BP fusion protein candidate, which is advancing into a Phase 2b trial in atopic dermatitis.
Separately, one research firm maintained coverage on the stock while lowering its price target to $26. Evommune currently trades at a market capitalization of approximately $185.63 million, with management citing a cash position supporting anticipated operations through 2028.
Conclusion
While the failed chronic spontaneous urticaria trial removes one potential indication for EVO756, Evommune's continued development across atopic dermatitis and migraine, along with progress on its separate EVO301 program, leaves multiple pipeline catalysts ahead. The company's extended cash runway through 2028 provides flexibility to pursue these remaining opportunities despite the setback.
This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.






Please wait processing your request...